AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Analysts see $5.8bn price tag for the privately held biotech as likely too high, but AbbVie is bullish on lead antibody-drug conjugate's potential in lung cancer. Focus on the acquisition shifted attention during the quarterly earnings call from disappointing sales for Viekira.